Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alkermes (ALKS) Research & Development (2016 - 2025)

Alkermes (ALKS) has disclosed Research & Development for 16 consecutive years, with $93.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 59.93% to $93.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $324.0 million, a 32.05% increase, with the full-year FY2025 number at $324.0 million, up 32.05% from a year prior.
  • Research & Development was $93.0 million for Q4 2025 at Alkermes, up from $81.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $118.4 million in Q3 2021 to a low of -$17.2 million in Q4 2021.
  • A 5-year average of $70.2 million and a median of $72.9 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 115.37% in 2021, then surged 546.62% in 2023.
  • Alkermes' Research & Development stood at -$17.2 million in 2021, then rose by 3.91% to -$16.6 million in 2022, then soared by 546.62% to $73.9 million in 2023, then dropped by 21.32% to $58.2 million in 2024, then surged by 59.93% to $93.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALKS's Research & Development are $93.0 million (Q4 2025), $81.7 million (Q3 2025), and $77.4 million (Q2 2025).